SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001387131-22-011400
Filing Date
2022-11-14
Accepted
2022-11-14 16:37:58
Documents
67
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT admp-10q_093022.htm   iXBRL 10-Q 1489924
2 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER ex31-1.htm EX-31.1 16694
3 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER ex31-2.htm EX-31.2 16362
4 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER ex32-1.htm EX-32.1 6440
5 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER ex32-2.htm EX-32.2 6434
  Complete submission text file 0001387131-22-011400.txt   6477799

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE admp-20220930.xsd EX-101.SCH 46017
7 XBRL CALCULATION FILE admp-20220930_cal.xml EX-101.CAL 87922
8 XBRL DEFINITION FILE admp-20220930_def.xml EX-101.DEF 196592
9 XBRL LABEL FILE admp-20220930_lab.xml EX-101.LAB 411251
10 XBRL PRESENTATION FILE admp-20220930_pre.xml EX-101.PRE 319280
61 EXTRACTED XBRL INSTANCE DOCUMENT admp-10q_093022_htm.xml XML 941364
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36242 | Film No.: 221386654
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences